102 related articles for article (PubMed ID: 21724579)
1. Oncogenic events associated with endometrial and ovarian cancers are rare in endometriosis.
Vestergaard AL; Thorup K; Knudsen UB; Munk T; Rosbach H; Poulsen JB; Guldberg P; Martensen PM
Mol Hum Reprod; 2011 Dec; 17(12):758-61. PubMed ID: 21724579
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.
Peterson LM; Kipp BR; Halling KC; Kerr SE; Smith DI; Distad TJ; Clayton AC; Medeiros F
Int J Gynecol Pathol; 2012 May; 31(3):195-205. PubMed ID: 22498935
[TBL] [Abstract][Full Text] [Related]
3. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
Ouerhani S; Elgaaied AB
Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
[TBL] [Abstract][Full Text] [Related]
4. KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: association with concurrent endometriosis.
Stewart CJ; Leung Y; Walsh MD; Walters RJ; Young JP; Buchanan DD
Hum Pathol; 2012 Aug; 43(8):1177-83. PubMed ID: 22305241
[TBL] [Abstract][Full Text] [Related]
5. RUNX3 is inactivated by promoter hypermethylation in malignant transformation of ovarian endometriosis.
Guo C; Ren F; Wang D; Li Y; Liu K; Liu S; Chen P
Oncol Rep; 2014 Dec; 32(6):2580-8. PubMed ID: 25333219
[TBL] [Abstract][Full Text] [Related]
6. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
7. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
[TBL] [Abstract][Full Text] [Related]
8. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer.
Gorringe KL; Choong DY; Williams LH; Ramakrishna M; Sridhar A; Qiu W; Bearfoot JL; Campbell IG
Neoplasia; 2008 Nov; 10(11):1253-8. PubMed ID: 18953434
[TBL] [Abstract][Full Text] [Related]
9. Mutations in the KRAS gene in ovarian tumors.
Dobrzycka B; Terlikowski SJ; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M
Folia Histochem Cytobiol; 2009; 47(2):221-4. PubMed ID: 19995707
[TBL] [Abstract][Full Text] [Related]
10. Low incidence of oncogenic EGFR, HRAS, and KRAS mutations in seborrheic keratosis.
Georgieva IA; Mauerer A; Groesser L; Herschberger E; Aslanidis C; Dietmaier W; Landthaler M; Hafner C
Am J Dermatopathol; 2014 Aug; 36(8):635-42. PubMed ID: 23739246
[TBL] [Abstract][Full Text] [Related]
11. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.
Nout RA; Bosse T; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; van Eijk R; Ter Haar NT; Smit VT
Gynecol Oncol; 2012 Sep; 126(3):466-73. PubMed ID: 22609107
[TBL] [Abstract][Full Text] [Related]
12. KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer.
Kohonen-Corish MR; Tseung J; Chan C; Currey N; Dent OF; Clarke S; Bokey L; Chapuis PH
Int J Cancer; 2014 Jun; 134(12):2820-8. PubMed ID: 24259266
[TBL] [Abstract][Full Text] [Related]
13. Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma.
Dobrzycka B; Terlikowski SJ; Mazurek A; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M
Folia Histochem Cytobiol; 2009; 47(1):65-8. PubMed ID: 19419940
[TBL] [Abstract][Full Text] [Related]
14. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
[TBL] [Abstract][Full Text] [Related]
15. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers.
Mutch DG; Powell MA; Mallon MA; Goodfellow PJ
Am J Obstet Gynecol; 2004 Apr; 190(4):935-42. PubMed ID: 15118616
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotypic analysis of ovarian endometrioid adenocarcinoma: correlation with KRAS mutation and the presence of endometriosis.
Stewart CJ; Walsh MD; Budgeon CA; Crook ML; Buchanan DB
Pathology; 2013 Oct; 45(6):559-66. PubMed ID: 24018808
[TBL] [Abstract][Full Text] [Related]
17. Methylation epigenotypes and genetic features in colorectal laterally spreading tumors.
Sakai E; Ohata K; Chiba H; Matsuhashi N; Doi N; Fukushima J; Endo H; Takahashi H; Tsuji S; Yagi K; Matsusaka K; Aburatani H; Nakajima A; Kaneda A
Int J Cancer; 2014 Oct; 135(7):1586-95. PubMed ID: 24590867
[TBL] [Abstract][Full Text] [Related]
18. The presence of KRAS, PPP2R1A and ARID1A mutations in 101 Chinese samples with ovarian endometriosis.
Zou Y; Zhou JY; Guo JB; Wang LQ; Luo Y; Zhang ZY; Liu FY; Tan J; Wang F; Huang OP
Mutat Res; 2018 May; 809():1-5. PubMed ID: 29547736
[TBL] [Abstract][Full Text] [Related]
19. Endocervical-like (Müllerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation.
Kim KR; Choi J; Hwang JE; Baik YA; Shim JY; Kim YM; Robboy SJ
Histopathology; 2010 Oct; 57(4):587-96. PubMed ID: 20955384
[TBL] [Abstract][Full Text] [Related]
20. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]